Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHO PharmaROCO:6586 -9.39%30 PB Ratio is 9.64 as of Jul. 14, 2026, which is 204% above its 10-year median of 3.17. GuruFocus rates ROCO:6586 with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, CHO Pharma ranks worse than 85.75% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-14), CHO Pharma's share price is NT$111.00. CHO Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was NT$11.51. Hence, CHO Pharma's PB Ratio of today is 9.64.
Warning Sign:
CHO Pharma Inc stock PB Ratio (=10.64) is close to 3-year high of 11.12.
The historical rank and industry rank for CHO Pharma's PB Ratio or its related term are showing as below:
ROCO:6586'
s PB Ratio Range Over the Past 10 Years
Min: 1.19 Med: 3.17 Max: 25
Current: 9.64
During the past 13 years, CHO Pharma's highest PB Ratio was 25.00. The lowest was 1.19. And the median was 3.17.
ROCO:6586's PB Ratio is ranked worse than 85.75% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs ROCO:6586: 9.64
During the past 12 months, CHO Pharma's average Book Value Per Share Growth Rate was -10.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -5.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CHO Pharma was 14.00% per year. The lowest was -14.30% per year. And the median was -8.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CHO Pharma PB Ratio Related Terms
CHO Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for CHO Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6586 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, CHO Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where CHO Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
CHO Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CHO Pharma (ROCO:6586) has a PB Ratio of 9.64 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CHO Pharma and its competitors. This is 204% above median its historical median of 3.17. Over the past decade, CHO Pharma's PB Ratio has ranged from 1.19 to 25.00. According to the industry distribution chart, CHO Pharma ranks #1053 out of 1228 companies in the Biotechnology industry, placing it in the top 85.7%.
Is CHO Pharma's PB Ratio too high?
CHO Pharma's current PB Ratio of 9.64 is 204% above median its 10-year median of 3.17. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 25.00. The Biotechnology industry median PB Ratio is 2.89. CHO Pharma's value of 9.64 is 234.1% above this industry median. Based on the distribution chart, CHO Pharma ranks #1053 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CHO Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CHO Pharma ranks #1053 out of 1228 companies for PB Ratio. This places CHO Pharma in the lower half of its industry. The industry median PB Ratio is 2.89. CHO Pharma's value of 9.64 is 234.1% above this benchmark. Historically, CHO Pharma's own PB Ratio has ranged from 1.19 to 25.00 over the past decade. While the company's 10-year median is 3.17 vs. the industry median of 2.89, CHO Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CHO Pharma's current PB Ratio of 9.64 is 234.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CHO Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHO Pharma's current PB Ratio is 9.64, which is 204% above median its own 10-year median of 3.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current PB Ratio of 9.64. The current PB Ratio is 9.64, which is 204% above median its 10-year median of 3.17 and 234.1% above the Biotechnology industry median of 2.89. CHO Pharma's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current PB Ratio is 9.64 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
30GF Score
Get the complete analysis for ROCO:6586
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6586 has been successfully added to your 
